Summary of Anixa Biosciences Conference Call Company Overview - **Company**: Anixa Biosciences (NasdaqCM: ANIX) - **Industry**: Biotechnology - **Focus**: Clinical stage biotech company with two early-stage clinical developments: a CAR T cell therapy for ovarian cancer and a breast cancer vaccine program [1][2] Key Points and Arguments Breast Cancer Vaccine Program - The breast cancer vaccine program is designed as both a treatment and prophylactic, focusing on a novel approach targeting a protein expressed only during lactation, which is produced by cancer cells in some breast cancer patients [6][7][8] - The phase one study presented at the 2025 San Antonio Breast Cancer Symposium showed promising results, with the data exceeding expectations and being superior to other cancer vaccines in phase one trials [9][10] Phase One Study Results - The phase one trial involved three cohorts of women: 1. Women with a history of triple-negative breast cancer at high risk of recurrence 2. Women with BRCA mutations who opted for prophylactic mastectomies 3. Women with residual disease post-treatment [10][12][13] - Key findings: - The vaccine was found to be safe with no significant side effects, only mild injection site irritation [11][18] - Strong immune responses were observed in 75% of participants [11][20] - No significant differences in immune response rates among the cohorts [21] Future Clinical Trials - Plans for a phase two study in a neoadjuvant setting, where newly diagnosed breast cancer patients will receive the vaccine alongside standard care (Keytruda) [24][25] - The trial is expected to enroll 80 to 100 women and take approximately two to three years to complete, with data available much sooner [29][31] - The goal is to demonstrate the vaccine's efficacy in reducing tumor burden before surgery, potentially leading to better outcomes and lower recurrence rates [25][27] Corporate Strategy and Partnerships - Anixa aims to establish pharmaceutical partnerships to fund further trials and commercialize the vaccine, reducing reliance on capital markets [28] - The IND has been transferred from Cleveland Clinic to Anixa, allowing the company to sponsor the trial [32] Broader Research Initiatives - Anixa is also advancing preclinical and R&D vaccine programs targeting other cancers, including ovarian, prostate, lung, and colon cancers, with a focus on identifying unique proteins associated with these cancers [34][35] Additional Important Insights - The approach of targeting unique proteins on cancer cells aims to avoid autoimmune responses, which is a significant advantage over traditional cancer vaccine strategies [7][35] - The company is optimistic about the potential for the breast cancer vaccine findings to be replicated in other cancer types, indicating a broader application of their research strategy [34][35]

Core Insights - Anixa Biosciences has completed the transfer of the Investigational New Drug application for its breast cancer vaccine from Cleveland Clinic, becoming the trial sponsor for its future development [1][2] - The company plans to advance the vaccine into a Phase 2 clinical trial after completing enrollment and observing encouraging immune response and safety data in the Phase 1 trial [2][4] - The breast cancer vaccine targets -lactalbumin, a protein that re-emerges in many forms of breast cancer, potentially offering therapeutic and preventive benefits [3] Company Overview - Anixa is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a portfolio that includes an ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center [5] - The company’s vaccine portfolio includes vaccines for breast and ovarian cancer, developed in collaboration with Cleveland Clinic, and aims to address various cancers by immunizing against "retired" proteins expressed in certain cancer forms [5] - Anixa's business model involves partnering with renowned research institutions to explore emerging technologies for further development and commercialization [5]

Anixa Biosciences Inc. (NASDAQ:ANIX) shares surged 15.21% in after-hours trading on Thursday, reaching $5.53, after the company presented final Phase 1 clinical trial data for its investigational breast cancer vaccine.Check out the current price of ANIX stock here.Phase 1 Trial ResultsThe healthcare company presented final data Thursday at the 2025 San Antonio Breast Cancer Symposium. The trial, conducted with the Cleveland Clinic and funded by a U.S. Department of Defense grant, showed the vaccine met all ...

®Combination of Keytruda and the vaccine generated T cell responses and showed no major additional side effects, supporting plans for a Phase 2 neoadjuvant combination study in newly diagnosed breast cancer patients Vaccine Was Safe and Well Tolerated at the Maximum Tolerated Dose Results Support Advancement of the Program into Phase 2 Development In Cohort Ic, a key objective was to assess whether administration of the investigational vaccine in combination with pembrolizumab could create intolerable side ...

Core Insights - Anixa Biosciences, Inc. is participating in the Water Tower Research Fireside Chat Series on December 15, 2025, with CEO Dr. Amit Kumar as a speaker [1][2] - The company focuses on cancer treatment and prevention, with a notable emphasis on ovarian cancer immunotherapy and vaccine development [2] Company Overview - Anixa is a clinical-stage biotechnology company specializing in cancer treatment and prevention [2] - The company is developing an ovarian cancer immunotherapy program in collaboration with Moffitt Cancer Center, utilizing a novel CAR-T technology called chimeric endocrine receptor-T cell (CER-T) [2] - Anixa's vaccine portfolio includes collaborations with Cleveland Clinic to develop vaccines for breast and ovarian cancer, as well as other cancers like lung, colon, and prostate [2] - The vaccines target "retired" proteins expressed in certain cancers, with exclusive licensing agreements in place with Cleveland Clinic for breast and ovarian cancer vaccines [2] Upcoming Events - The Fireside Chat will be hosted by Robert Sassoon, Managing Director – Healthcare at Water Tower Research, and is open to all investors [2] - Final data from Anixa's Phase 1 breast cancer vaccine trial will be presented on December 11, 2025, at the San Antonio Breast Cancer Symposium [5]

At 7:25 a.m. ET on Wednesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening bell.For active traders, premarket trading offers a head start in spotting potential breakouts, reversals, or sharp price swings. These early moves often indicate where momentum may carry into the regular session, making premarket analysis a key part of the trading day.In the Green - Premarket GainersThe following stocks are trading hi ...

Core Insights - Anixa Biosciences is a clinical stage biotech company focused on developing innovative CAR-T cell therapy for ovarian cancer and a vaccine for breast cancer [2] Company Overview - Anixa is listed on NASDAQ under the ticker ANIX [2] - The company is engaged in the development of additional predevelopment candidates beyond its primary therapies [2] Leadership - Dr. Amit Kumar serves as the Chairman and CEO of Anixa Biosciences [1]

Core Insights - Anixa Biosciences has received approval from the WHO for the non-proprietary name "liraltagene autoleucel" for its CAR-T therapy targeting recurrent ovarian cancer, marking a significant milestone in its development and potential commercialization [1][2][3] Company Overview - Anixa Biosciences is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a therapeutic portfolio that includes an ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center [4] - The company utilizes a novel CAR-T technology known as chimeric endocrine receptor-T cell (CER-T) therapy, which targets the follicle stimulating hormone receptor (FSHR) expressed on ovarian cells and certain cancer cells [3][4] Clinical Development - The ongoing Phase 1 trial of liraltagene autoleucel is designed to evaluate safety, identify the maximum tolerated dose, and monitor clinical activity in adult women with recurrent ovarian cancer who have progressed after at least two prior therapies [3][4] - The trial is being conducted in partnership with Moffitt Cancer Center, a leader in cancer immunotherapy [2][4] Future Directions - The approval of the non-proprietary name allows Anixa to establish a universally recognized name for its CAR-T therapy, facilitating clearer identification and safe prescription of the drug [2][3] - The company plans to transition to using the name liraltagene autoleucel, or lira-cel, in future communications [2]

Group 1 - Water Tower Research (WTR) experienced a technical issue during a recent Fireside Chat with Anixa Biosciences, leading to an interruption in the live broadcast [1] - The session was fully recorded and is now available for on-demand viewing [1] - WTR's CEO, Shawn Severson, apologized for the inconvenience and stated that the technical issue has been resolved to ensure future sessions proceed without interruption [1] Group 2 - The Fireside Chat Series by Water Tower Research aims to connect investors with management teams from innovative public and private companies through open-access discussions [1] - Water Tower Research focuses on modernizing investor engagement through research-driven communications, providing equal access to high-quality company research for all investors [3] - The company distributes its research and investor content across various platforms, including traditional research aggregators and social media, to enhance investor relations [3]

Core Insights - Anixa Biosciences has received a patent for its breast cancer vaccine technology, which targets the -lactalbumin protein, a promising approach for immunoprevention strategies against breast cancer [1][2][3] Company Overview - Anixa Biosciences is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a strong emphasis on developing next-generation preventive immunotherapies [2][5] - The company has a collaboration with Cleveland Clinic for the development of its breast cancer vaccine, which is part of a broader portfolio that includes ovarian cancer immunotherapy [5] Patent and Intellectual Property - The U.S. Patent Number 12,472,205 will be issued on November 18, 2025, extending the intellectual property protection for Anixa's breast cancer vaccine technology into the mid-2040s [1][2] - This patent reinforces the company's commitment to addressing breast cancer, which is projected to affect nearly 300,000 women in the U.S. by 2026 [1][3] Market Need - Breast cancer remains the most commonly diagnosed cancer among women globally, with over 297,000 new cases expected in the U.S. in 2025 and approximately 43,000 deaths anticipated [3] - There is currently no FDA-approved vaccine for breast cancer prevention, highlighting a significant unmet need in preventive oncology [3] Vaccine Mechanism - Anixa's investigational vaccine aims to stimulate the immune system to recognize and eliminate cells expressing -lactalbumin while sparing normal tissue, potentially minimizing off-target effects [4]